FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022791140> ?p ?o ?g. }

• W2022791140 endingPage "221" @default.
• W2022791140 startingPage "209" @default.
• W2022791140 abstract "This study compares the surface characteristics and surface energetics of two potential bulking excipients, anhydrous sub-micron alpha-lactose and sub-micron sucrose, for use with low-dose, suspension formulations in pressurised metered dose inhalers (pMDIs). Both sub-micron bulking excipients are processed from parent materials (alpha-lactose monohydrate/alpha-lactose monohydrate and silk grade sucrose, respectively) so the surface characteristics of each material were determined and compared. Additionally, the surface energetics and adhesive interactions between each sub-micron bulking excipient and some chosen active pharmaceutical ingredients (APIs) used in pMDI formulations were also determined. From this data, it was possible to predict the potential degree of interaction between the APIs and each sub-micron bulking excipient, thus determining suitable API-excipient combinations for pMDI formulation optimisation. Salmon calcitonin was also investigated as a potential API due to the current interest in, and the potential low-dose requirements for, the pulmonary delivery of proteins.The size and morphology of each sub-micron excipient (and parent materials) were determined using scanning electron microscopy (SEM) and the crystalline nature of each sub-micron excipient and parent material was assessed using X-ray diffraction (XRD). The surface chemistry of each sub-micron excipient was analysed using X-ray photoelectron spectroscopy (XPS). The surface energies of each sub-micron excipient, along with their respective parent materials and any intermediates, were determined using two techniques. The surface energies of these materials were determined via (a) single particle adhesive interactions using atomic force microscopy (AFM) and (b) 'bulk' material surface interactions using contact angle measurements (CA). From the CA data, it was possible to calculate the theoretical work of adhesion values for each API-excipient interaction using the surface component analysis (SCA). The Young's modulus for each sub-micron excipient and parent material was also determined using AFM. Finally, the adhesive interactions were determined between each sub-micron bulking excipient and five APIs (formoterol fumarate, salmeterol xinafoate, salbutamol sulphate, mometasone furoate and salmon calcitonin).Both sub-micron sucrose and anhydrous sub-micron alpha-lactose exhibited a lower surface free energy than their respective parent materials/intermediates. In addition, both AFM and CA surface energy measurements also showed that sub-micron sucrose has a higher surface energy than anhydrous sub-micron alpha-lactose. Theoretical work of adhesion values between anhydrous sub-micron alpha-lactose and each API are considerably lower than those observed between micronised alpha-lactose monohydrate and each API. Corresponding theoretical work of adhesion values between sub-micron sucrose and each API were almost identical to those observed between silk grade sucrose and each API. Young's modulus determination revealed that sub-micron sucrose has a greater crystal hardness/elasticity ratio than anhydrous sub-micron alpha-lactose. With the exception of salmon calcitonin, sub-micron sucrose showed larger adhesive interactions to the selected APIs than anhydrous sub-micron alpha-lactose.Anhydrous sub-micron alpha-lactose has been found to have lower adhesive interactions with a range of chosen, low-dose APIs compared to sub-micron sucrose. This could be related to the lower surface energy for anhydrous sub-micron alpha-lactose. Knowledge of the surface free energy and mechanical properties of potential sub-micron bulking excipients and API materials could provide useful information regarding the selection of suitable API-submicron bulking excipient combinations during the development and optimisation stages of suspension pMDI formulations." @default.
• W2022791140 created "2016-06-24" @default.
• W2022791140 creator A5000799051 @default.
• W2022791140 creator A5009976577 @default.
• W2022791140 creator A5015040094 @default.
• W2022791140 creator A5022843606 @default.
• W2022791140 creator A5024869694 @default.
• W2022791140 creator A5037182926 @default.
• W2022791140 date "2008-09-01" @default.
• W2022791140 modified "2023-09-26" @default.
• W2022791140 title "The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers" @default.
• W2022791140 cites W1504310960 @default.
• W2022791140 cites W1866460952 @default.
• W2022791140 cites W1966407643 @default.
• W2022791140 cites W1970108759 @default.
• W2022791140 cites W1971992525 @default.
• W2022791140 cites W1972327857 @default.
• W2022791140 cites W1987930740 @default.
• W2022791140 cites W1993004731 @default.
• W2022791140 cites W2000395553 @default.
• W2022791140 cites W2005440881 @default.
• W2022791140 cites W2011643272 @default.
• W2022791140 cites W2016971948 @default.
• W2022791140 cites W2020128960 @default.
• W2022791140 cites W2021996583 @default.
• W2022791140 cites W2022019243 @default.
• W2022791140 cites W2022069744 @default.
• W2022791140 cites W2026841370 @default.
• W2022791140 cites W2033789057 @default.
• W2022791140 cites W2040343906 @default.
• W2022791140 cites W2042666460 @default.
• W2022791140 cites W2045467856 @default.
• W2022791140 cites W2046341176 @default.
• W2022791140 cites W2046533979 @default.
• W2022791140 cites W2048494198 @default.
• W2022791140 cites W2052523402 @default.
• W2022791140 cites W2054004613 @default.
• W2022791140 cites W2056805649 @default.
• W2022791140 cites W2057383956 @default.
• W2022791140 cites W2068805835 @default.
• W2022791140 cites W2069042376 @default.
• W2022791140 cites W2069321448 @default.
• W2022791140 cites W2075506397 @default.
• W2022791140 cites W2081884774 @default.
• W2022791140 cites W2084194047 @default.
• W2022791140 cites W2114869300 @default.
• W2022791140 cites W2116457340 @default.
• W2022791140 cites W4244714950 @default.
• W2022791140 doi "https://doi.org/10.1016/j.ijpharm.2008.05.032" @default.
• W2022791140 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18577435" @default.
• W2022791140 hasPublicationYear "2008" @default.
• W2022791140 type Work @default.
• W2022791140 sameAs 2022791140 @default.
• W2022791140 citedByCount "29" @default.
• W2022791140 countsByYear W20227911402012 @default.
• W2022791140 countsByYear W20227911402013 @default.
• W2022791140 countsByYear W20227911402014 @default.
• W2022791140 countsByYear W20227911402015 @default.
• W2022791140 countsByYear W20227911402016 @default.
• W2022791140 countsByYear W20227911402021 @default.
• W2022791140 countsByYear W20227911402022 @default.
• W2022791140 crossrefType "journal-article" @default.
• W2022791140 hasAuthorship W2022791140A5000799051 @default.
• W2022791140 hasAuthorship W2022791140A5009976577 @default.
• W2022791140 hasAuthorship W2022791140A5015040094 @default.
• W2022791140 hasAuthorship W2022791140A5022843606 @default.
• W2022791140 hasAuthorship W2022791140A5024869694 @default.
• W2022791140 hasAuthorship W2022791140A5037182926 @default.
• W2022791140 hasConcept C127413603 @default.
• W2022791140 hasConcept C159985019 @default.
• W2022791140 hasConcept C178790620 @default.
• W2022791140 hasConcept C185592680 @default.
• W2022791140 hasConcept C192562407 @default.
• W2022791140 hasConcept C26771246 @default.
• W2022791140 hasConcept C2777239854 @default.
• W2022791140 hasConcept C2778724459 @default.
• W2022791140 hasConcept C42360764 @default.
• W2022791140 hasConcept C43617362 @default.
• W2022791140 hasConcept C77281830 @default.
• W2022791140 hasConceptScore W2022791140C127413603 @default.
• W2022791140 hasConceptScore W2022791140C159985019 @default.
• W2022791140 hasConceptScore W2022791140C178790620 @default.
• W2022791140 hasConceptScore W2022791140C185592680 @default.
• W2022791140 hasConceptScore W2022791140C192562407 @default.
• W2022791140 hasConceptScore W2022791140C26771246 @default.
• W2022791140 hasConceptScore W2022791140C2777239854 @default.
• W2022791140 hasConceptScore W2022791140C2778724459 @default.
• W2022791140 hasConceptScore W2022791140C42360764 @default.
• W2022791140 hasConceptScore W2022791140C43617362 @default.
• W2022791140 hasConceptScore W2022791140C77281830 @default.
• W2022791140 hasIssue "1-2" @default.
• W2022791140 hasLocation W20227911401 @default.
• W2022791140 hasLocation W20227911402 @default.
• W2022791140 hasOpenAccess W2022791140 @default.
• W2022791140 hasPrimaryLocation W20227911401 @default.
• W2022791140 hasRelatedWork W1515830010 @default.
• W2022791140 hasRelatedWork W1980354333 @default.
• W2022791140 hasRelatedWork W2053854213 @default.

• next